Renal pathophysiology and pharmacological mechanisms of nephroprotection
Copyright © 2023. Publicado por Elsevier España, S.L.U..
Several risk factors may affect the progression of chronic kidney disease (CKD). Arterial hypertension, proteinuria, obesity, intraglomerular hypertension, smoking and metabolic control in diabetes mellitus are the main modifiable risk factors for progression. The progression of CKD involves many cellular processes that originate in specific compartments of the kidney, the vascular compartment with nephroangiosclerosis and the tubulointerstitial compartment with fibrosis and tubulointerstitial atrophy, and there may be overlap between both mechanisms. Given the involvement of so many risk factors and so many pathogenic pathways in the progression of CKD, the best hope for delaying or preventing the progression of CKD lies in a combined and multidisciplinary therapeutic approach, based on the existing evidence and acting on all these processes and pathways from the mechanistic point of view, and on a global process that is cardiovascular and renal risk to improve the prognosis of patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 Suppl 1 |
|---|---|
| Enthalten in: |
Semergen - 49 Suppl 1(2023) vom: 24. Juni, Seite 102021 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Fisiopatología renal y mecanismos farmacológicos de nefroprotección |
|---|
| Beteiligte Personen: |
Górriz, J L [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.06.2023 Date Revised 26.06.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.semerg.2023.102021 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358566665 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358566665 | ||
| 003 | DE-627 | ||
| 005 | 20231226075025.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.1016/j.semerg.2023.102021 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1195.xml |
| 035 | |a (DE-627)NLM358566665 | ||
| 035 | |a (NLM)37355300 | ||
| 035 | |a (PII)S1138-3593(23)00100-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Górriz, J L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Renal pathophysiology and pharmacological mechanisms of nephroprotection |
| 246 | 3 | 3 | |a Fisiopatología renal y mecanismos farmacológicos de nefroprotección |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.06.2023 | ||
| 500 | |a Date Revised 26.06.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Publicado por Elsevier España, S.L.U. | ||
| 520 | |a Several risk factors may affect the progression of chronic kidney disease (CKD). Arterial hypertension, proteinuria, obesity, intraglomerular hypertension, smoking and metabolic control in diabetes mellitus are the main modifiable risk factors for progression. The progression of CKD involves many cellular processes that originate in specific compartments of the kidney, the vascular compartment with nephroangiosclerosis and the tubulointerstitial compartment with fibrosis and tubulointerstitial atrophy, and there may be overlap between both mechanisms. Given the involvement of so many risk factors and so many pathogenic pathways in the progression of CKD, the best hope for delaying or preventing the progression of CKD lies in a combined and multidisciplinary therapeutic approach, based on the existing evidence and acting on all these processes and pathways from the mechanistic point of view, and on a global process that is cardiovascular and renal risk to improve the prognosis of patients | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Bloqueo del sistema renina angiotensina | |
| 650 | 4 | |a Chronic kidney disease | |
| 650 | 4 | |a Enfermedad renal crónica | |
| 650 | 4 | |a Fibrosis intersticial | |
| 650 | 4 | |a Interstitial fibrosis | |
| 650 | 4 | |a Nefroangioesclerosis | |
| 650 | 4 | |a Nephroangiosclerosis | |
| 650 | 4 | |a Progresión renal | |
| 650 | 4 | |a Proteinuria | |
| 650 | 4 | |a Renal progression | |
| 650 | 4 | |a Renin angiotensin system blockade | |
| 700 | 1 | |a Górriz-Zambrano, C |e verfasserin |4 aut | |
| 700 | 1 | |a Pallarés-Carratalá, V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Semergen |d 1998 |g 49 Suppl 1(2023) vom: 24. Juni, Seite 102021 |w (DE-627)NLM095511652 |x 1578-8865 |7 nnns |
| 773 | 1 | 8 | |g volume:49 Suppl 1 |g year:2023 |g day:24 |g month:06 |g pages:102021 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.semerg.2023.102021 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 Suppl 1 |j 2023 |b 24 |c 06 |h 102021 | ||